IPL Advisers’s iShares Biotechnology ETF IBB Stock Holding History

IPL Advisers’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-68,898	Closed	-$6.09M	–	20
2016 Q4	$6.09M	Buy	+68,898	New	+$6.27M	1.69%	17

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

IPL Advisers's IBB Position: Q1 2017 in Review

IPL Advisers sold out of iShares Biotechnology ETF (IBB) in Q1 2017, closing a stake of 68,898 shares — an estimated $6.09M sold.

IPL Advisers first reported a position in IBB in Q4 2016 and held it in 1 quarter. The position peaked at $6.09M in Q4 2016. 520 funds tracked by Wall St. Rank hold IBB as of Q1 2017.

IPL Advisers reported no remaining iShares Biotechnology ETF position as of Q1 2017 after selling out during the quarter.
IPL Advisers sold 68,898 iShares Biotechnology ETF shares in Q1 2017, an estimated $6.09M.
IPL Advisers first reported a position in iShares Biotechnology ETF in Q4 2016 and held it in 1 quarter.
IPL Advisers's iShares Biotechnology ETF position peaked at $6.09M in Q4 2016.
520 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2017.

Based on IPL Advisers's 13F filing for Q1 2017, filed 15 May 2017.